Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) received a $3.0 million payment from Future Pak after Jaguar terminated the buy-back provision in its January 2026 U.S. licensing agreement for Mytesi and Canalevia-CA1. Jaguar earlier received $16.0 million of non-dilutive capital, with $2.0 million contingent and up to $20.0 million in future milestones.
Jaguar will continue manufacturing both crofelemer products while Future Pak holds U.S. marketing rights; Jaguar targets an NDA filing for MVID in H1 2027 and is pursuing Breakthrough Therapy designation.
Positive
- Received $3.0M termination payment from Future Pak
- Earlier received $16.0M non-dilutive capital in January 2026
- Potential $20.0M in milestone and future payments
- Continuing to manufacture Mytesi and Canalevia-CA1
Negative
- Granted Future Pak exclusive U.S. marketing rights for crofelemer products
- Terminated buy-back option, relinquishing unilateral repurchase right
- Additional $2.0M remains contingent on post-closing conditions
Market Reaction – JAGX
Following this news, JAGX has declined 24.97%, reflecting a significant negative market reaction. Our momentum scanner has triggered 23 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.60. This price movement has removed approximately $835K from the company's valuation. Trading volume is above average at 2.0x the average, suggesting increased trading activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, JAGX was down 0.77% while close peers showed mixed moves: QNRX up 2.16%, GRI up 3.25%, AZTR down 10.59%, ONCO down 1.5%. Momentum scanner data also flags a mix of up and down moves, suggesting stock-specific factors rather than a clear sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Special dividend record | Positive | -0.8% | Reminder of record date for special Series O stock dividend. |
| Feb 18 | Special dividend announced | Positive | +0.6% | Announcement of one-time Series O stock dividend and dilution protection aims. |
| Jan 22 | Strategy and funding update | Positive | -9.8% | Highlight of $16M license upfront and rare intestinal failure focus. |
| Jan 14 | Investor summit presentation | Positive | +10.6% | Upcoming catalyst-focused presentation at Lytham Partners summit. |
| Jan 12 | License deal signed | Positive | -20.9% | New U.S. license agreement for Mytesi and Canalevia-CA1 with upfront cash. |
Recent history shows multiple instances where positive, non-dilutive funding and licensing news coincided with negative price reactions, while more routine or event-focused updates sometimes aligned with price gains.
Over the past few months, Jaguar has repeatedly highlighted non-dilutive financing and strategic focus on crofelemer for rare intestinal failure. The January 12, 2026 and January 22, 2026 license-related updates, involving upfront and milestone payments, were followed by notable declines. In contrast, an investor summit presentation on January 15, 2026 coincided with a double‑digit gain. February and March communications emphasized a special Series O stock dividend intended to mitigate dilution concerns. Today’s added $3M non-dilutive payment fits this ongoing capital-raising and refocusing narrative.
Regulatory & Risk Context
The company has an effective S-3 shelf registration filed on October 3, 2025, expiring on October 3, 2028. The shelf has been used at least once, as indicated by a 424B3 filing on November 25, 2025, providing flexibility to raise capital subject to the terms and remaining capacity disclosed in SEC filings.
Market Pulse Summary
The stock is dropping -25.0% following this news. A negative reaction despite additional non-dilutive cash would fit a recent pattern where upbeat funding and licensing news coincided with selling pressure. The company now references a $3 million payment tied to its Future Pak agreement, on top of $16M received earlier, and is targeting an NDA in 1H 2027. Investors have also faced dilution-related overhangs and an effective S-3 shelf from October 3, 2025, factors that could weigh on sentiment even when operational updates are constructive.
Key Terms
parenteral support medical
total parenteral nutrition medical
breakthrough therapy designation regulatory
nda regulatory
AI-generated analysis. Not financial advice.
As announced, Jaguar received an up-front payment of
SAN FRANCISCO, CA / ACCESS Newswire / March 3, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that its wholly-owned subsidiary Napo Pharmaceuticals, Inc. (collectively, with Jaguar Health, Inc., "Jaguar") has received a
Under the terms of the agreement, Future Pak became the exclusive marketer for Mytesi (crofelemer), Jaguar's FDA-approved novel prescription drug for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, and Canalevia-CA1, Jaguar's crofelemer prescription drug for the treatment of chemotherapy-induced diarrhea in dogs. Jaguar was provided with
"As announced, the agreement has a buy-back option that provides Jaguar with the unilateral right to repurchase all of the licensed rights from Future Pak starting five years after the agreement effective date, provided that certain regulatory milestones are met," said Lisa Conte, Jaguar's founder, president, and CEO. "Per the terms of the agreement, Jaguar receives
"Our agreement with Future Pak is fully aligned with our strategy to concentrate Jaguar's crofelemer development efforts on human rare-disease indications, particularly intestinal failure, where we continue to advance business development discussions with additional potential partners," Conte said.
Crofelemer continues to advance as a potential treatment for rare forms of intestinal failure, including intestinal failure due to short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). Multiple investigator-initiated and company-sponsored studies of crofelemer are ongoing in the U.S., the European Union and the United Arab Emirates, with initial proof-of-concept data showing significant reductions in parenteral support (PS) requirements in pediatric MVID and SBS-IF patients.
Jaguar's intestinal failure program is expected to continue to provide clinical proof-of-concept milestones, and the company is targeting Breakthrough Therapy designation for crofelemer for the indication of MVID, with a planned filing of an NDA (New Drug Application) with the U.S. Food and Drug Administration for this indication in the first half of 2027.
Intestinal failure is a debilitating condition that often requires patients to receive life-sustaining fluids, electrolytes and nutrients through intravenous administration, which consists of total parenteral nutrition (TPN) with supplemental intravenous fluids, which together constitute PS. Many intestinal failure patients require PS up to 7 days a week, and sometimes for 20 hours or more per day. While crucial for intestinal failure patients, PS is associated with significant toxicities to patients, similar to some toxicities associated with chemotherapy, often causing serious health problems including infections, metabolic complications, and liver and kidney function problems. These symptoms may emerge at any time in intestinal failure patients and often become life-threatening.
About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Important Safety Information About Canalevia®-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling.Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
See full Prescribing Information at Canalevia.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that its intestinal failure program will continue to provide clinical proof-of-concept milestones, Jaguar's expectation that the company will apply for Breakthrough Therapy designation for crofelemer for the indication of MVID, and Jaguar's expectation that it will file an NDA with the U.S. Food and Drug Administration for this indication in the first half of 2027. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
Why did Jaguar Health (JAGX) receive a $3 million payment from Future Pak on March 3, 2026?
How much capital did Jaguar Health (JAGX) obtain from the January 2026 Future Pak licensing agreement?
What rights does Future Pak have for Mytesi and Canalevia-CA1 under the JAGX agreement?
How does the Future Pak deal affect Jaguar Health's (JAGX) crofelemer development strategy?
What clinical and regulatory milestones is Jaguar Health (JAGX) targeting for crofelemer?
Will Jaguar Health (JAGX) still manufacture Mytesi after the Future Pak licensing agreement?
